1585 related articles for article (PubMed ID: 28700791)
1. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.
Dunn KE; Weerts EM; Huhn AS; Schroeder JR; Tompkins DA; Bigelow GE; Strain EC
Addict Biol; 2020 Jan; 25(1):e12680. PubMed ID: 30295400
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
5. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.
Dunn K; Bergeria C; Huhn AS; Strain EC
Drug Alcohol Depend; 2020 Oct; 215():108212. PubMed ID: 32781310
[TBL] [Abstract][Full Text] [Related]
6. Buprenorphine for managing opioid withdrawal.
Gowing L; Ali R; White JM; Mbewe D
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD002025. PubMed ID: 28220474
[TBL] [Abstract][Full Text] [Related]
7. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.
Shulman M; Greiner MG; Tafessu HM; Opara O; Ohrtman K; Potter K; Hefner K; Jelstrom E; Rosenthal RN; Wenzel K; Fishman M; Rotrosen J; Ghitza UE; Nunes EV; Bisaga A
JAMA Netw Open; 2024 May; 7(5):e249744. PubMed ID: 38717773
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone shortened opioid detoxification with buprenorphine.
Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
[TBL] [Abstract][Full Text] [Related]
9. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
[TBL] [Abstract][Full Text] [Related]
10. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
[TBL] [Abstract][Full Text] [Related]
11. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
[TBL] [Abstract][Full Text] [Related]
14. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
[TBL] [Abstract][Full Text] [Related]
15. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Collins ED; Kleber HD; Whittington RA; Heitler NE
JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
[TBL] [Abstract][Full Text] [Related]
17. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal.
Srivastava A; Kahan M; Njoroge I; Sommer LZ
Can Fam Physician; 2019 May; 65(5):e214-e220. PubMed ID: 31088887
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Huhn AS; Finan PH; Gamaldo CE; Hammond AS; Umbricht A; Bergeria CL; Strain EC; Dunn KE
Sci Transl Med; 2022 Jun; 14(650):eabn8238. PubMed ID: 35731889
[TBL] [Abstract][Full Text] [Related]
20. Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG; Carroll KM; Shi JM; Schottenfeld RS; Kosten TR; Rounsaville BJ
Ann Intern Med; 1997 Oct; 127(7):526-30. PubMed ID: 9313020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
